Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.
Genital herpes simplex virus (HSV) infections are common but results from vaccine trials with HSV-2 glycoprotein D (gD) have been disappointing. We therefore compared a similar HSV gD2 vaccine, to a further truncated gD2 vaccine, to a vaccine with gD2 plus gB2 and gH2/gL2 and to a vaccine with only gB2 and gH2/gL2 in a guinea pig model of genital herpes. All vaccines were administered with cationic liposome-DNA complexes (CLDC) as an adjuvant. All vaccines significantly decreased the severity of acute genital disease and vaginal virus replication compared to the placebo group. The majority of animals in all groups developed at least one episode of recurrent disease but the frequency of recurrent disease was significantly reduced by each vaccine compared to placebo. No vaccine was significantly more protective than gD2 alone for any of the parameters described above. No vaccine decreased recurrent virus shedding. When protection against acute infection of dorsal root ganglia and the spinal cord was evaluated all vaccines decreased the per cent of animal with detectable virus and the quantity of virus but again no vaccine was significantly more protective than another. Improvements in HSV-2 vaccines may require inclusion of more T cell targets, more potent adjuvants or live virus vaccines.
Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA. David.Bernstein@cchmc.org
David I
DI
Bernstein
Julie D
JD
Earwood
Fernando J
FJ
Bravo
Gary H
GH
Cohen
Roselyn J
RJ
Eisenberg
Jennifer R
JR
Clark
Jeffrey
J
Fairman
Rhonda D
RD
Cardin
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D005727:Ganglia, Spinal / Q000821:virology; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000276:immunology / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D018258:Herpesvirus 2, Human / Q000276:immunology; D008081:Liposomes / Q000494:pharmacology; D009500:Neutralization Tests; D013116:Spinal Cord / Q000821:virology; D014759:Viral Envelope Proteins / Q000276:immunology*; D017735:Virus Latency; D017201:Virus Shedding
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D022301:Herpes Simplex Virus Vaccines; D008081:Liposomes; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2
J Virol. 1999 Dec;73(12):9879-90
10559300
J Gen Virol. 1998 Feb;79 ( Pt 2):353-61
9472620
J Virol. 2010 Dec;84(24):12691-702
20943978
J Infect Dis. 1993 Mar;167(3):731-5
8382722
J Virol. 2010 Nov;84(22):11646-60
20826693
Vaccine. 2010 May 7;28(21):3748-53
19857450
J Infect Dis. 2005 Dec 15;192(12):2117-23
16288376
J Immunol. 2008 Jan 1;180(1):426-37
18097044
Vaccine. 2009 Jun 12;27(29):3811-20
19406188
Lancet. 2007 Dec 22;370(9605):2127-37
18156035
J Infect Dis. 2009 Oct 1;200(7):1088-95
19702506
Hum Vaccin. 2009 Mar;5(3):141-50
18690014
J Infect Dis. 2003 Feb 15;187(4):542-9
12599070
J Virol. 1999 Oct;73(10):8127-37
10482562
Nat Struct Mol Biol. 2010 Jul;17(7):882-8
20601960
Virology. 2000 Sep 15;275(1):1-8
11017782
J Immunol. 2001 Mar 15;166(6):4049-58
11238653
J Virol. 1994 May;68(5):2803-10
7512152
Vaccine. 1996 Feb;14(2):107-12
8852405
Virol J. 2006 Jul 05;3:54
16822314
J Immunol. 2001 Sep 15;167(6):3324-8
11544321
Sex Transm Dis. 1985 Jan-Mar;12(1):33-9
2988143
J Infect Dis. 2008 Oct 15;198(8):1098-100
18783317
Viral Immunol. 2006 Summer;19(2):220-36
16817765
J Infect Dis. 1987 May;155(5):914-20
3031173
Cell Mol Life Sci. 2008 Jun;65(11):1653-68
18351291
J Infect Dis. 2003 May 15;187(10):1509-12
12721930
J Virol. 1998 Jul;72(7):5937-47
9621056
J Infect Dis. 2001 Oct 15;184(8):964-71
11574910
Vaccine. 1997 Jun;15(8):857-60
9234533
J Virol. 1998 Sep;72(9):7091-8
9696802
Nat Med. 2008 Feb;14(2):205-12
18193057
J Immunol. 1999 Aug 1;163(3):1552-61
10415059
JAMA. 1999 Jul 28;282(4):331-40
10432030
J Virol. 1998 Jan;72(1):65-72
9420201
Clin Vaccine Immunol. 2009 May;16(5):699-705
19279167
Herpes. 2001 Mar;8 Suppl 1:6A-10A
11867028
N Engl J Med. 2002 Nov 21;347(21):1652-61
12444179
J Immunol. 2006 Jun 15;176(12):7335-45
16751377
Annu Rev Med. 2008;59:381-95
18186706
EMBO J. 2005 Dec 7;24(23):4144-53
16292345
Methods Mol Med. 1998;10:131-56
21374226
J Virol. 1994 Feb;68(2):766-75
8289380